178 related articles for article (PubMed ID: 23530980)
1. Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³.
Lucero C; Torres B; León A; Calvo M; Leal L; Pérez I; Plana M; Arnedo M; Mallolas J; Gatell JM; García F
AIDS Res Hum Retroviruses; 2013 Aug; 29(8):1161-7. PubMed ID: 23530980
[TBL] [Abstract][Full Text] [Related]
2. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
3. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
Kowalska JD; Reekie J; Mocroft A; Reiss P; Ledergerber B; Gatell J; d'Arminio Monforte A; Phillips A; Lundgren JD; Kirk O;
AIDS; 2012 Jan; 26(3):315-23. PubMed ID: 22112597
[TBL] [Abstract][Full Text] [Related]
4. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
5. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata.
Reekie J; Gatell JM; Yust I; Bakowska E; Rakhmanova A; Losso M; Krasnov M; Francioli P; Kowalska JD; Mocroft A;
AIDS; 2011 Nov; 25(18):2259-68. PubMed ID: 21918422
[TBL] [Abstract][Full Text] [Related]
6. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.
Marin B; Thiébaut R; Bucher HC; Rondeau V; Costagliola D; Dorrucci M; Hamouda O; Prins M; Walker S; Porter K; Sabin C; Chêne G
AIDS; 2009 Aug; 23(13):1743-53. PubMed ID: 19571723
[TBL] [Abstract][Full Text] [Related]
7. Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study.
; Judd A; Chappell E; Turkova A; Le Coeur S; Noguera-Julian A; Goetghebuer T; Doerholt K; Galli L; Pajkrt D; Marques L; Collins IJ; Gibb DM; González Tome MI; Navarro M; Warszawski J; Königs C; Spoulou V; Prata F; Chiappini E; Naver L; Giaquinto C; Thorne C; Marczynska M; Okhonskaia L; Posfay-Barbe K; Ounchanum P; Techakunakorn P; Kiseleva G; Malyuta R; Volokha A; Ene L; Goodall R
PLoS Med; 2018 Jan; 15(1):e1002491. PubMed ID: 29381702
[TBL] [Abstract][Full Text] [Related]
8. Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART.
Lapadula G; Chatenoud L; Gori A; Castelli F; Di Giambenedetto S; Fabbiani M; Maggiolo F; Focà E; Ladisa N; Sighinolfi L; Di Pietro M; Pan A; Torti C;
PLoS One; 2015; 10(5):e0124741. PubMed ID: 26020949
[TBL] [Abstract][Full Text] [Related]
9. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
10. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort.
Pacheco YM; Jarrin I; Rosado I; Campins AA; Berenguer J; Iribarren JA; Rivero M; Muñoz-Medina L; Bernal-Morell E; Gutiérrez F; Leal M;
Antiviral Res; 2015 May; 117():69-74. PubMed ID: 25766861
[TBL] [Abstract][Full Text] [Related]
11. The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.
Mocroft A; Bannister WP; Kirk O; Kowalska JD; Reiss P; D'Arminio-Monforte A; Gatell J; Fisher M; Trocha H; Rakhmanova A; Lundgren JD;
Antivir Ther; 2012; 17(7):1291-300. PubMed ID: 23013779
[TBL] [Abstract][Full Text] [Related]
12. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
[TBL] [Abstract][Full Text] [Related]
13. Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study.
Ferry T; Raffi F; Collin-Filleul F; Dupon M; Dellamonica P; Waldner A; Strady C; Chêne G; Leport C; Moing VL;
J Acquir Immune Defic Syndr; 2009 Aug; 51(4):407-15. PubMed ID: 19474755
[TBL] [Abstract][Full Text] [Related]
14. Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy.
Zhang S; van Sighem A; Kesselring A; Gras L; Prins JM; Hassink E; Kauffmann R; Richter C; de Wolf F; Reiss P;
HIV Med; 2015 May; 16(5):265-72. PubMed ID: 25604160
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.
; Lanoy E; May M; Mocroft A; Phillip A; Justice A; Chêne G; Furrer H; Sterling T; Monforte AD; Force L; Gill J; Harris R; Hogg RS; Rockstroh J; Saag M; Khaykin P; de Wolf F; Sterne JA; Costagliola D
AIDS; 2009 Oct; 23(16):2199-208. PubMed ID: 19779320
[TBL] [Abstract][Full Text] [Related]
16. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.
Kousignian I; Abgrall S; Grabar S; Mahamat A; Teicher E; Rouveix E; Costagliola D;
Clin Infect Dis; 2008 Jan; 46(2):296-304. PubMed ID: 18171266
[TBL] [Abstract][Full Text] [Related]
17. Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort.
Mussini C; Galli L; Lepri AC; De Luca A; Antinori A; Libertone R; Angarano G; Bonfanti P; Castagna A; DʼArminio Monforte A;
J Acquir Immune Defic Syndr; 2013 Jul; 63(3):339-45. PubMed ID: 23591636
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.
Mussini C; Lorenzini P; Puoti M; Lichtner M; Lapadula G; Di Giambenedetto S; Antinori A; Madeddu G; Cozzi-Lepri A; d'Arminio Monforte A; De Luca A;
PLoS One; 2015; 10(12):e0140877. PubMed ID: 26640953
[TBL] [Abstract][Full Text] [Related]
19. AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based cohort studies.
Luz PM; Bruyand M; Ribeiro S; Bonnet F; Moreira RI; Hessamfar M; Campos DP; Greib C; Cazanave C; Veloso VG; Dabis F; Grinsztejn B; Chêne G;
BMC Infect Dis; 2014 May; 14():278. PubMed ID: 24885790
[TBL] [Abstract][Full Text] [Related]
20. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care.
McCombe JA; Vivithanaporn P; Gill MJ; Power C
HIV Med; 2013 Feb; 14(2):99-107. PubMed ID: 22994556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
